Bristol Myers Squibb Reports Q1 2026 Earnings with Mixed Revenue Performance
Bristol Myers Squibb (BMY) reported Q1 2026 earnings with total revenue of $11.5 billion, a 1% year-over-year increase. The growth portfolio saw a 9% rise in sales, driven by products like Reblozyl and Breyanzi, while Opdivo revenue declined 8% due to inventory drawdowns. Eliquis and Camzyos showed strong growth, but some products faced challenges ahead of price reductions.
Tickers: $BMY
Topics: Earnings Report Market Adoption Pharmaceutical Industry Product Sales Revenue Growth